A recent clinical study reported that a combination of Ipilimumab (anti-CTLA-4 mAb) and Bevacizumab (anti-VEGF mAb) exhibited promising activity with a predictable and manageable toxicity profile in glioblastoma [177]. Here, VEGFA is linked to glioblastoma.